Oncotarget targets holistic approaches to cancer

Those who suffer from papillary thyroid carcinoma already know going into it that they will likely get to the point where there is no hope to defeat their cancer. This is because papillary thyroid carcinoma so often develops a bodily resistance to vemurafenib. The reason this bodily resistance occurs to the medicine is that vemurafenib specifically target a mutated BRAF gene. The body sees vemurafenib as a foreign agent in the same category as a virus. It then responds to vemurafenib by sending white blood cells to defeat it. This drug-resistant cancer so often gets to the point that it becomes incurable and those with papillary thyroid carcinoma must accept their fate that they will die from this cancer. Follow Oncotarget on Linkedin.

The nationally peer-reviewed Oncotarget Journal recently sat down with Dr. Carmelo Nucero to discuss his latest research that suggests there is a way to stop papillary thyroid carcinoma from becoming drug-resistant. Oncotarget is a holistic peer-reviewed journal that focuses on the pathological consequences that occur to a patient who is diagnosed with cancer and undergoes cancer treatment.

Dr. Carmelo Nucero is reporting that he has discovered a way to decrease the likelihood that papillary thyroid carcinoma will become resistant to vemurafenib. For those who may not know, vemurafenib is the most common drug used to treat this most common kind of thyroid cancer. If Dr. Carmelo Nucero can get papillary thyroid carcinoma to stop resisting vemurafenib, then he will be able to keep papillary thyroid carcinoma curable for the majority of patients.

Dr. Carmelo Nucero discovered that if the drug palbociclib, which is used to treat women with stage IV breast cancer, is mixed with vemurafenib the nearly miraculous results happen. Learn more at researchgate.net

He found that the combination of these drugs, when used in a therapeutic way, can induce stronger cancer cell death while also promoting healthier cell regeneration. He is hopeful that since both vemurafenib and palbociclib have already been approved by the FDA as solitary drugs that after a few months of trials they can be approved together. Stay tuned on Oncotarget’s podcast for more information which is coming soon.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/